Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Dr. Lal PathLabs Limited ( (IN:LALPATHLAB) ) has shared an announcement.
Dr. Lal PathLabs’ board has approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026 and recommended a final dividend of ₹4 per share, with a record date of 26 June 2026. The company is also strengthening its governance and oversight by reappointing Ernst & Young LLP as internal auditor and A.G. Agarwal & Associates as cost auditor for FY 2026-27.
In a bid to deepen its market presence, Dr. Lal PathLabs will acquire 100% of Shahbazkers Diagnostic Centre, turning it into a wholly owned subsidiary. The diagnostics major is further pursuing international expansion with the incorporation of a wholly owned subsidiary in Dubai, while reinforcing leadership continuity through the proposed re-appointment of Executive Chairman (Hony) Brig. Dr. Arvind Lal and independent director Rajit Mehta, and elevating key scientific and lab management heads to senior management roles.
More about Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited is a leading Indian diagnostics chain that provides pathology and laboratory testing services across the country. The company focuses on clinical lab services for patients, hospitals and healthcare providers, and is expanding its presence both domestically through acquisitions and internationally via new subsidiaries.
Average Trading Volume: 36,605
Technical Sentiment Signal: Buy
Current Market Cap: 234.2B INR
For an in-depth examination of LALPATHLAB stock, go to TipRanks’ Overview page.